PreveCeutical closes $455,000 second tranche of private placement

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) completed the second tranche of its non-brokered private placement, raising $455,000 through the issuance of 11,375,000 units at $0.04 per unit.

Each unit consists of one common share and one-half share purchase warrant. The warrants allow holders to purchase additional shares at $0.06 each for 24 months from the closing date. The company retains an acceleration right to shorten the warrant expiry period if shares trade at $0.18 or higher for 10 consecutive trading days on the Canadian Securities Exchange.

The Vancouver-based company paid $29,200 in finder's fees and issued 730,000 finder's warrants in connection with the closing. The finder's warrants carry the same exercise terms as the unit warrants.

PreveCeutical plans to use the proceeds to pay outstanding payables, cover operating expenses, and support general working capital requirements. All securities issued carry a four-month-plus-one-day hold period under applicable securities laws.

The second tranche forms part of a previously announced $1,200,000 private placement offering. The company had announced the offering in prior releases dated August 5, September 5, and October 10, 2025.

PreveCeutical operates as a health sciences company developing preventive and curative therapies using organic and nature-identical products. The company maintains five research and development programs covering areas including dual gene therapy for diabetes and obesity, peptide treatments, and concussion therapy products.

You May Also Be Interested In

• PreveCeutical closes second tranche of private placement for $245,000
• Lockheed Martin wins $2.8B in Defense contracts for F-35, helicopters
• 22nd Century Group files prospectus for warrant share resale